NCT02396069View on ClinicalTrials.gov

The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Stroke
Interventions
DRUG

JPI-289

PARP-1 inhibitor

DRUG

Placebo

Placebo

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY